Chemotherapy, immunocompetence, immunosuppression and prognosis in acute leukemia.
D000328:Adult; D000368:Aged; D000906:Antibodies / Q000032:analysis; D000941:Antigens; D003520:Cyclophosphamide / Q000627:therapeutic use; D003561:Cytarabine / Q000627:therapeutic use; D005260:Female; D006433:Hemocyanins; D006801:Humans; D006968:Hypersensitivity, Delayed; D007111:Immunity, Cellular; D007153:Immunologic Deficiency Syndromes / Q000150:complications; D007165:Immunosuppression Therapy; D037102:Lectins; D015470:Leukemia, Myeloid, Acute / Q000150:complications / Q000175:diagnosis / Q000188:drug therapy* / Q000276:immunology*; D007958:Leukocyte Count; D008213:Lymphocyte Activation; D008214:Lymphocytes / Q000276:immunology; D008297:Male; D015122:Mercaptopurine / Q000627:therapeutic use; D008727:Methotrexate / Q000627:therapeutic use; D011241:Prednisone / Q000627:therapeutic use; D011379:Prognosis; D012075:Remission, Spontaneous; D012882:Skin Tests; D013866:Thioguanine / Q000627:therapeutic use; D014750:Vincristine / Q000627:therapeutic use
D000906:Antibodies; D000941:Antigens; D037102:Lectins; D003561:Cytarabine; D014750:Vincristine; D003520:Cyclophosphamide; D006433:Hemocyanins; D015122:Mercaptopurine; D013866:Thioguanine; D011241:Prednisone; D008727:Methotrexate